Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01993004 · ClinicalTrials.gov registry record
Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells
A clinical trial, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- 24
- Enrollment target
NCT01993004 is a clinical trial that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 24 participants.
The verdict
NCT01993004 has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported in many human diseases. The purpose of this pilot study is to determine if microRNA expression is changed in untreated and glatiramer acetate-treated patients with multiple sclerosis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01993004
The ClinicalTrials.gov registry entry for NCT01993004 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01993004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01993004 about?
NCT01993004 is a clinical study titled "Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells". MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported in many human diseases. The purpose of this pilot study is to determine if microRNA expression is changed in untreated and glatiramer acetate-treated patients with multiple sclerosis.
What is the current status of trial NCT01993004?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2013-07. Estimated completion is 2015-12.
Who is sponsoring clinical trial NCT01993004?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.